Switching To or From Oral Micronized Progesterone (Prometrium): Protocols, Timing, and Clinical Evidence

This article is pending qualified clinical review. It describes general prescribing patterns reported in the literature and does not replace individualized guidance from the clinician managing your hormone therapy.

Oral micronized progesterone (OMP, brand name Prometrium) is bioidentical progesterone in a peanut-oil-suspended capsule, FDA-approved for endometrial protection in postmenopausal women taking estrogen who still have a uterus. It is a different molecule from synthetic progestins such as medroxyprogesterone acetate (MPA, brand Provera) and norethindrone acetate (NETA), and different again from dydrogesterone, a retro-isomer of progesterone used outside the United States. In most published protocols, moving between OMP and a synthetic progestin does not require a washout period; the switch is generally made at the boundary of a dosing cycle, matching the regimen (continuous daily or cyclic 12-to-14-day) that is already in place. What changes with the switch is not just the hormone but the side-effect profile, the bleeding pattern during the transition, and, for some patients, the monitoring plan. None of this is a substitute for a clinician reviewing the individual patient's bleeding history, endometrial imaging, liver function, and allergy status before a switch.

The core answer, with its boundary

Across the trial and cohort literature on progestogen substitution in hormone therapy, oral micronized progesterone and medroxyprogesterone acetate have shown broadly comparable endometrial protection when dosed appropriately, while differing in their effects on lipids, mood, and possibly breast tissue outcomes reported in observational cohorts. This comparative safety picture comes mainly from a mix of older randomized comparisons (the PEPI trial being the most frequently cited) and large observational cohorts, not from head-to-head trials powered for hard outcomes like fracture, cardiovascular events, or breast cancer mortality. Anyone using these findings to justify a switch should treat the direction of the association as more established than the size of the effect, and should confirm current numbers against the primary papers before quoting them to a patient.

Do you need a washout period to switch progestogens?

Generally no, for the switches most commonly performed in HRT: MPA to OMP, NETA to OMP, dydrogesterone to OMP, and the reverse of each. Because these agents act on the same progesterone receptor pathway (with different receptor cross-reactivity, discussed below), clinicians typically stop one agent and start the next at the point in the cycle where the next dose would have been due, the start of a new calendar month for continuous regimens, or the start of the next 12-to-14-day progestin phase for cyclic regimens. The exception is switching to or from an intrauterine progestogen delivery system, where a brief overlap is used deliberately (see below), and switching to or from a compounded (non-FDA-approved) progesterone product, where extra caution and endometrial reassessment are reasonable given uncertain potency.

How oral micronized progesterone differs mechanistically from synthetic progestins

OMP has the same molecular structure as endogenous progesterone. After oral dosing it undergoes substantial first-pass hepatic metabolism, and one of its metabolites, allopregnanolone, is a positive allosteric modulator at GABA-A receptors. This is the physiological basis for the sedation many patients notice, which is why OMP is usually dosed at bedtime. Synthetic progestins like MPA do not generate meaningful allopregnanolone and do not produce this effect. MPA and NETA also have off-target activity at the androgen and glucocorticoid receptors that OMP largely lacks, which is the plausible explanation (not a proven causal chain in every patient) for reports that switching to OMP resolves complaints such as acne, oily skin, or bloating attributed to those synthetic agents. Exact pharmacokinetic figures (peak concentration, half-life, particle size effects on absorption) are reported in the pharmacology literature but are not reproduced here with specific numbers pending verification against the primary source papers.

Why clinicians switch patients onto OMP

The most commonly cited reasons in practice are:

• Lipid effects. The PEPI trial, a multi-arm randomized comparison from the 1990s, is the most frequently cited source for the claim that MPA lowers HDL cholesterol relative to estrogen alone, while cyclic OMP did not show the same reduction. This is real trial evidence, but it is decades old and used doses and formulations specific to that era; it should be treated as directionally informative rather than a precise modern effect size.
• Breast tissue observations. A large French cohort study (the E3N cohort) reported a difference in breast cancer risk between estrogen combined with synthetic progestins versus estrogen combined with micronized progesterone, with the micronized progesterone group not showing a statistically significant increase over follow-up. This is observational, not randomized, evidence. It cannot establish that switching an individual patient from a synthetic progestin to OMP lowers her personal breast cancer risk; it can only inform a discussion about relative population-level associations.
• Mood and quality of life. Some comparative studies have reported improved mood measures in women switched from MPA to OMP, but sample sizes have generally been small and results should be treated as suggestive rather than definitive.
• Endometrial protection with a different side-effect trade. Both agents are used because they oppose estrogen-driven endometrial proliferation; the choice between them is mostly about tolerability, not about one being categorically safer for the endometrium.

Some patients switch in the other direction, from OMP toward a synthetic progestin or an intrauterine device, most often because of excessive sedation, peanut allergy, or persistent breakthrough bleeding despite adequate OMP dosing.

Switching from MPA (Provera) to OMP

This is the switch performed most often in HRT practice.

• Continuous regimen: MPA 2.5 mg daily is commonly substituted with OMP 100 mg nightly.
• Cyclic regimen: MPA 5 to 10 mg for 12 to 14 days per month is commonly substituted with OMP 200 mg nightly for the same 12 to 14 day window.

Some clinicians use a higher OMP dose for the first few cycles in patients with prior findings of endometrial thickening, then reassess. This is a matter of individual clinical judgment rather than a labeled protocol, and the decision belongs to the prescribing clinician working from the patient's own ultrasound and biopsy history, not from a fixed rule.

Bleeding patterns often change for two to three cycles after the switch. This is expected and, by itself, is not evidence of endometrial pathology, but bleeding that does not settle within that window should prompt evaluation rather than reassurance.

Switching from norethindrone acetate (NETA) to OMP

NETA is the progestogen component of several combined estrogen/progestin products. Because these are fixed-dose combination pills, switching to OMP requires unbundling the estrogen and progestogen:

1. Replace the combination product with a standalone estrogen (oral or transdermal) at an appropriate dose, chosen by the prescriber.
2. Add OMP, either 100 mg nightly continuous or 200 mg nightly for 12 to 14 days cyclic, depending on the regimen already in use.

No washout is needed between stopping NETA and starting OMP; the progestogen switch can occur the same day the estrogen-only product is started. Because NETA has androgenic activity that OMP does not share, patients may notice changes in skin, hair growth, or libido in either direction after the switch, and this trade-off is worth discussing before making the change, not just after.

Switching from OMP to a levonorgestrel intrauterine system (Mirena)

For patients who want to stop oral progestogen entirely, a levonorgestrel-releasing IUD delivers progestin locally to the endometrium while systemic estrogen therapy continues. In the United States, the FDA-approved indication for this device is contraception and heavy menstrual bleeding; using it for endometrial protection during estrogen therapy is an off-label use supported by clinical trial data outside the US label, and clinicians who prescribe it this way should say so plainly to the patient.

A commonly used transition protocol is to insert the IUD and continue OMP for one additional cycle (about 14 days) to maintain endometrial suppression while the device reaches steady local levonorgestrel levels, then stop OMP. Comparative studies have reported that the IUD suppresses endometrial proliferation about as effectively as cyclic OMP over extended follow-up, with fewer withdrawal bleeding episodes, though exact rates vary by study and should be checked against the primary paper before being quoted to a patient.

Switching from dydrogesterone to OMP

Dydrogesterone (Duphaston) is used widely in Europe and parts of Asia but is not FDA-approved or marketed in the United States. Patients relocating, or seeking a bioidentical alternative, sometimes need to switch.

Published comparative work on endometrial effects has proposed rough dose mappings, commonly cited as dydrogesterone 10 mg approximating cyclic OMP 200 mg, and dydrogesterone 5 mg daily approximating continuous OMP 100 mg, but these equivalences come from separate studies using different endpoints and populations, not a single head-to-head trial, so they should be treated as an approximate starting point for clinician judgment rather than a fixed conversion. No washout is generally used; the switch is made at the start of the next cycle or the next calendar day for continuous regimens. Patients should be told in advance that OMP produces a sedative effect that dydrogesterone does not, and advised to take it at bedtime.

A separate, more recent line of evidence is worth flagging as a boundary case rather than direct support: a 2026 pilot randomized trial (REMODEL) compared dydrogesterone with vaginal micronized progesterone for luteal-phase support in frozen embryo transfer cycles (pubmed.ncbi.nlm.nih.gov/42077438). That trial's population (women undergoing fertility treatment), route (vaginal, not oral), and clinical question (luteal support for implantation, not endometrial protection during menopausal hormone therapy) are different enough from the switching scenario described here that it should not be used to justify dosing decisions in menopausal HRT. It is included because it is the most current primary evidence on dydrogesterone-versus-progesterone substitution, and it illustrates that this comparison is still an active research question with population-specific answers rather than one settled equivalence that transfers across indications.

Compounded versus FDA-approved oral micronized progesterone

Patients sometimes ask about switching between Prometrium and a compounded progesterone capsule from a compounding pharmacy. This is not a like-for-like substitution. Compounded oral progesterone products are not required to demonstrate bioequivalence to Prometrium, and independent testing of compounded hormone products has repeatedly found potency variability, both above and below the labeled dose. The Endocrine Society's scientific statement on compounded bioidentical hormones has concluded that there is no established scientific basis for compounded hormones being safer or more effective than FDA-approved formulations. If a patient is moving from a compounded product to Prometrium, or the reverse, a clinician may reasonably want an endometrial check around the time of the switch to rule out under-protection that could have gone unnoticed on the compounded product.

Special populations

• Peanut allergy: Prometrium capsules contain peanut oil and carry a contraindication for patients with peanut allergy. Alternatives are a synthetic progestin, the levonorgestrel IUD, or a non-oral progesterone formulation that avoids peanut oil, chosen with the prescriber.
• Hepatic impairment: Because OMP undergoes substantial first-pass liver metabolism, impaired hepatic clearance can raise and prolong serum levels and worsen sedation. Vaginal micronized progesterone, which bypasses first-pass metabolism, is one alternative discussed in the literature for patients who cannot tolerate oral dosing for this reason; this is a route change, not simply a dose change, and should be managed by the prescriber.
• Enzyme-inducing anticonvulsants (carbamazepine, phenytoin, phenobarbital): These drugs can accelerate progesterone clearance through hepatic enzyme induction, and some patients on these medications may need a higher OMP dose or a switch to an intrauterine progestogen delivery system that is not affected by hepatic enzyme induction. This interaction is pharmacologically plausible and reported in the literature; specific dose adjustments should be individualized, not taken from a general chart.

Monitoring after a progestogen switch

Bleeding pattern is the main practical surveillance tool after any switch. Breakthrough or unscheduled bleeding in the first two to three cycles is common and, alone, is not a red flag. Bleeding that persists beyond about three months, or heavy bleeding at any point, is generally regarded as a reason for evaluation, typically starting with transvaginal ultrasound and proceeding to endometrial biopsy if endometrial thickness is increased. Guideline bodies including the North American Menopause Society and the American College of Obstetricians and Gynecologists have published general positions along these lines; the precise thresholds in current guidance should be checked directly rather than assumed, since guideline numbers are periodically revised.

Routine serum progesterone monitoring is not standard for oral formulations because levels vary widely between individuals and change quickly after each dose. It has limited practical use outside a specific question about adherence, and even then should be interpreted by the prescribing clinician rather than compared against a fixed cutoff by the patient.

Evidence boundary: what is established, what is not

Established: OMP and MPA both provide endometrial protection against estrogen-driven proliferation when dosed appropriately; the mechanisms and receptor selectivity differences between OMP and synthetic progestins are well described in pharmacology literature; Prometrium is contraindicated in peanut allergy; compounded hormone products are not required to prove bioequivalence to FDA-approved products.

Plausible but not proven at the individual-patient level: That switching from a synthetic progestin to OMP lowers an individual patient's breast cancer risk, improves her mood, or improves her cardiovascular risk profile. The supporting studies are largely observational cohorts or small trials, and none of them are designed to prove causation for an individual switch decision.

Not established: A single universally correct dose-equivalence table across MPA, NETA, dydrogesterone, and OMP that applies to every patient regardless of indication, dose history, and bleeding pattern. Published equivalences are approximate and drawn from different studies with different endpoints.

When to seek urgent care rather than wait for a routine follow-up

Heavy bleeding that soaks through protection within an hour, bleeding with dizziness or fainting, sudden chest pain, sudden severe headache, sudden vision changes, or leg swelling with pain in someone on hormone therapy warrants urgent evaluation rather than waiting for a scheduled follow-up. These are not specific to a progestogen switch, but a recent hormone regimen change is worth mentioning to whoever evaluates you.

A framework for discussing and monitoring a progestogen switch with your clinician

Use this as a conversation and monitoring structure, not as a substitute for the plan your own clinician sets.

Stop-and-escalate conditions, regardless of checkpoint timing:

• Heavy bleeding, bleeding with dizziness, or bleeding after a period of no bleeding at all in a postmenopausal patient
• New severe headache, chest pain, leg swelling and pain, or vision changes
• Signs suggesting an allergic reaction after starting Prometrium in a patient with unknown or borderline peanut allergy status
• Sedation severe enough to affect driving or daily function that does not improve after dose-timing adjustment

Where label guidance ends and individualized judgment begins: The FDA label defines an approved indication and general dosing range for OMP; it does not specify how to convert from MPA, NETA, or dydrogesterone, how long to overlap during an IUD transition, or how to adjust dosing for enzyme-inducing anticonvulsants. Those decisions come from clinical literature interpreted by the prescriber for the individual patient, and that is exactly where a second opinion or a more detailed discussion is worth asking for if something about your situation feels like it does not fit a standard pattern.

References

• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995. (Verify current citation and figures before quoting specific numbers.)
• Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008. (Observational cohort; verify current citation before quoting risk figures.)
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022. (Verify current statement wording and thresholds directly with NAMS.)
• Santoro N, et al. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2016. (Verify current citation before quoting.)
• Lobo RA, et al. A 17β-estradiol/progesterone oral capsule for vasomotor symptoms in postmenopausal women (REPLENISH trial). Obstet Gynecol. 2018. (Verify current citation and outcome figures before quoting.)
• Dydrogesterone versus micronized vaginal progesterone for luteal phase support in artificial cycle frozen embryo transfer (REMODEL): a pilot prospective randomized controlled trial. 2026. https://pubmed.ncbi.nlm.nih.gov/42077438/ (Different population and route from menopausal HRT; included for context on dydrogesterone-progesterone comparisons, not as direct support for HRT switching doses.)